{"entity":{"id":"lancet","kind":"journal","name":"The Lancet","aka":["Lancet"],"tldr":"The Lancet is Britain's leading general medical journal and the other main home of practice-changing cancer trials, with a stronger global-health and policy voice than NEJM.","summary":"The Lancet appears weekly and publishes practice-changing oncology phase 3 trials (CheckMate 649, KEYNOTE-048, CARTITUDE-1, TRANSFORM), the Global Burden of Disease series, and Lancet Commissions that shape cancer policy. Elsevier hybrid model: subscription with an open-access option; abstracts free. Known for editorial campaigning on health inequality and for the HPV-vaccination and cancer-survival population studies that appear in this corpus.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/The_Lancet","links":[{"label":"Oncology collection","url":"https://www.thelancet.com/clinical/diseases/cancer"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/lancet/home","issn":"0140-6736","scope":"general medicine","access":"hybrid","founded":1823,"impactFactor":{"value":98.4,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["The Lancet","Lancet"]},"route":"/journals/lancet/","neighbours":{"paper":[{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/"},{"id":"paper-propsma-hofman-lancet-2020","kind":"paper","name":"proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer","route":"/key-papers/paper-propsma-hofman-lancet-2020/"}]}}